These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
124 related items for PubMed ID: 1116106
1. A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: a Southwest Oncology Group study. Tranum BL, Haut A, Rivkin S, Weber E, Quagliana JM, Shaw M, Tucker WG, Smith FE, Samson M, Gottlieb J. Cancer; 1975 Apr; 35(4):1148-53. PubMed ID: 1116106 [Abstract] [Full Text] [Related]
2. Growth curve modification of measurable tumors by 75 mg/m2 of CCNU every 3 weeks. Israel L, Chahinian P, Accard JL, Choffel C, Combes PF, Danrigal A, Germouty J, Migueres J, Schaerer R, Sotto JJ. Eur J Cancer (1965); 1973 Apr; 9(11-12):789-97. PubMed ID: 4804306 [No Abstract] [Full Text] [Related]
3. Phase II study of CCNU (NSC-79037) in the treatment of advanced gastrointestinal cancer. Klaassen DJ, Rapp E. Cancer Chemother Rep; 1974 Apr; 58(5 Pt 1):667-9. PubMed ID: 4426046 [No Abstract] [Full Text] [Related]
4. Role of a nitrosourea (CCNU, NSC-79037) in advanced nonhematologic cancer. Perloff M, Muggia FM, Ackerman C. Cancer Chemother Rep; 1974 Apr; 58(3):421-4. PubMed ID: 4841718 [No Abstract] [Full Text] [Related]
5. Methyl-CCNU inclinical cancer therapy. Wasserman TH, Slavik M, Carter SK. Cancer Treat Rev; 1974 Dec; 1(4):251-69. PubMed ID: 4377543 [No Abstract] [Full Text] [Related]
6. Study of methyl-CCNU(NSC-95441) in the treatment of lung cancer. Richards F, Pajak TF, Cooper MR, Spurr CL. Cancer Chemother Rep; 1973 Dec; 57(4):419-22. PubMed ID: 4357670 [No Abstract] [Full Text] [Related]
7. Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma. Maurice P, Glidewell O, Jacquillat C, Silver RT, Carey R, Pas AT, Cornell CJ, Burningham RA, Nissen NI, Holland JF. Cancer; 1978 May; 41(5):1658-63. PubMed ID: 348294 [Abstract] [Full Text] [Related]
10. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. De Jager R, Cappelaere P, Armand JP, Keiling R, Fargeot P, Bastit P, van Glabbeke M, Renard J, Earl H, Rubens R. Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006 [Abstract] [Full Text] [Related]
12. Combination chemotherapy with 1-(2-chloroethyl-3-cyclohexyl-1-nitrosourea) (CCNU), vincristine and methotrexate in primary and metastatic brain tumors--a preliminary report. Hildebrand J, Brihaye J, Wagenknecht L, Michel J, Kenis Y. Eur J Cancer (1965); 1973 Sep; 9(9):627-34. PubMed ID: 4803230 [No Abstract] [Full Text] [Related]
13. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271). Cunningham TJ, Nemoto T, Rosner D, Knight E, Taylor S, Rosenbaum C, Horton J, Dao T. Cancer Chemother Rep; 1974 Sep; 58(5 Pt 1):677-81. PubMed ID: 4138966 [No Abstract] [Full Text] [Related]
18. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4]. Brunner KW, Maurice P, Sonntag RW. Schweiz Med Wochenschr; 1972 Oct 28; 102(43):1546-51. PubMed ID: 4647016 [No Abstract] [Full Text] [Related]